0VGI trade ideas
TG Therapeutics (TGTX) Analysis Company Overview: TG Therapeutics NASDAQ:TGTX is a biopharmaceutical company focused on developing and commercializing innovative treatments for B-cell diseases. The company's recent FDA approval of BRIUMVI for relapsing multiple sclerosis (RMS) marks a significant milestone, positioning TG Therapeutics to capitalize on a high-demand therapeutic area.
Key Developments:
FDA Approval of BRIUMVI: The approval of BRIUMVI for relapsing multiple sclerosis opens access to a substantial market, with nearly 1 million individuals in the U.S. affected by RMS. This provides a significant revenue opportunity, with BRIUMVI offering a new treatment option that has shown favorable efficacy, safety, and convenient dosing compared to existing therapies.
Positive Market Reception: CEO Michael S. Weiss has expressed strong confidence in BRIUMVI's potential, noting positive feedback from both healthcare providers and patients. The drug's unique value proposition lies in its twice-yearly dosing, which is more convenient than the monthly or quarterly regimens offered by competitors, enhancing patient compliance and satisfaction.
Pipeline and Future Growth: The successful launch of BRIUMVI is a testament to TG Therapeutics' ability to introduce novel treatments. This sets a strong foundation for future developments in B-cell disease therapies, as the company explores additional indications and expands its pipeline. BRIUMVI's performance in the market could pave the way for further advancements in TG Therapeutics' product offerings.
Investment Outlook: Bullish Outlook: We are bullish on TGTX above the $21.00-$22.00 range, driven by the strong initial reception of BRIUMVI and its potential to capture a significant share of the RMS market. Upside Potential: Our price target for TG Therapeutics is set at $34.00-$35.00, reflecting the expected revenue growth from BRIUMVI and the company's strategic positioning in the biopharma sector.
🚀 TGTX—Leading the Way in B-cell Disease Therapies! #BiopharmaInnovation #MultipleSclerosis #NewTreatmentOptions
New Setup: TGTXTGTX: I have a green setup signal(dot Indictor). It has an excellent risk-to-reward ratio(RR:). I'm looking to enter long near the close of the day if the stock can manage to CLOSE above the last candle highs(white line). If triggered, I will then place a stop-loss below(SL) and a price target above it(TP).
********
Note: The above setups will remain valid until the stock CLOSES BELOW my set stop-loss level.
Short potential on TGTXShort-term structural looks bullish for TGTX.
But looking on bigger perspective TGTX is having structural bearishnes for years.
Possible short setup at 30ish level.
TGTX, 3/1-3/8, -2% lossOn 2/28/2024, TG Therapeutics (TGTX) reported a loss of $0.09 per share on revenue of $43.97 million for the fourth quarter ended December 2023. The consensus estimate was a loss of $0.12 per share on revenue of $40.06 million.
TGTX Its a point where it can go buy from, but its a weak price point at $17 - $18. it has to show me a reversal pattern to consider buying from those prices.
The best situation is if the price decreases to around $13 - $14 to buy until $25 that's 80% growth.
TG Therapeutics Gains After Strong Q3 BeatTG Therapeutics (NASDAQ:TGTX) added ~21% pre-market Wednesday after the company posted solid topline and bottom-line beats with its Q3 2023 financials.
The Morrisville, North Carolina-based biotech reported $165.8M in net revenue for the quarter, up from $94M in the prior-year period, exceeding the consensus by as much as $102.5M.
A one-time payment of $140M from Neuraxpharm, its ex-U.S. partner for multiple sclerosis therapy Briumvi, boosted the top line.
However, Briumvi's net sales also exceeded the company's expectations, reaching $25.1M from $16M in Q2 2023. The FDA approved the anti-CD20 monoclonal antibody in late 2022, leading to its commercial launch in January.
TG Therapeutics (TGTX) recorded 900 Briumvi prescriptions for Q3, taking the total prescriptions for the drug to 2,200 since its launch.
Meanwhile, the company's SG&A expenses reached $32.8M, a twofold rise from Q2 2022. However, given the strong topline growth, TG Therapeutics (TGTX) reported $113.9M in net income compared to $35.8M of net loss in the prior year period.
$TGTX 4R trade ideaTGTX on pullback to the OB can benefit with a 4R is my thought. let me know what you think
$TGTX LongFalling wedge within a larger broadening wedge.
Daily hidden bullish divergence.
Strong bull trend above the 150MA.
$TGTX - Pullback and consolidationTop trading idea for next week(s)!
NASDAQ:TGTX already proved itself with a strong performance YTD of 125% (and 580% in a year).
The stock is in a clear stage 2 uptrend and is now consolidating in between the 21 day MA and 50 day EMA on lower volume (check weekly chart).
Has the fundamentals.
A few more days of tight consolidation or a quick retest of the 50 EMA would make it even a better setup and creates a launchpad.
Entry would be around 28.27
Stop breach of the 50 on high volume or a tight stop low of the day (when it breaks the pivot).
Enjoy next week!
Other similar ideas: NYSE:SKX , NASDAQ:WING and NASDAQ:ARCT
Pullback Buy in TGTXBiotech stocks can make huge moves, and this one is no exception.
TGTX more than doubled in a month and is showing no signs of slowing down.
Slower-trending, blue chip stocks tend to ride their 50-day moving average (red line on chart) on the way up.
Stronger stocks tend to hold their 21-day moving average (blue line).
But with high-flying honey badger stocks like TGTX, you are lucky to get a pullback to the 10-day (yellow line).
TGTX touched its 10-day exponential moving average on Friday, making this the first real pullback buying opportunity since the initial surge.
I would consider buying here with an 8-10% stop loss.
TG Therapeutics. Boom! TGTXWe are moving up.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
TGTX is Bull. Entering Trend Channel (after Elliot Wave)TGTX is Bull and it is entering the Trend Channel. It made an Elliot Wave, and it is rebounding to the trend. Its growth will also be fueled by XBI which is also bullish.
Elliot Wave (Failed Breakout) creates long-term growth potentialTGTX made an Elliot Wave but it failed to continue the trend after the Correction Wave and it collapsed.
However, The Elliot Impulse Wave did create potential for TGTX because it built up a good Trend Channel.
To continue to grow, it would need to enter Trend Channel first and then stabilize within it.
The green dotted line is where it needs to go.
Note: This is for Educational Purposes Only.
Trend Reversal Confluencing Signals.Confluencing trend reversal signals as described in 'Price Action Breakdown'.
I have yet to effectively apply the reading. Still trying to make sense of it. using it only when appropriate. that sort of thing.
Buliish MACD divergence on 1D $TGTXGetting into long position with TGTX. Aslo suits for long term investment
this is what i like to seei think TGTX has an FDA approval coming up and a great cup and handle it can break out of
im excited to see the price action on this on be patient with the entry
good luck!
if anyone knows lmk when the FDA approval is
TGTX possibly breaking out of a long basing formationAfter failing to follow through on the 02/05 breakout, were now back at the 50ma with a gap fill along with decreasing volume. I think this is a hit or a miss, it'll most likely bounce strongly and make new highs or continue grinding down through the 50ma.
TGTX, enters Downtrend as Momentum drops below 0 level on Jan 14This indicator may be signaling that TGTX's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. Tickeron's A.I.dvisor backtested 83 similar cases where TGTX's Momentum Indicator fell below the 0 level, and 71 of them led to a successful outcome. Odds of Success: 86%. Current price $50.00 is above $29.61 the highest resistance line found by Tickeron A.I. Throughout the month of 12/11/20 - 01/14/21, the price experienced a +21% Uptrend, while the week of 01/07/21 - 01/14/21 shows a -5% Downtrend.
Bearish Trend Analysis
The 10-day RSI Indicator for TGTX moved out of overbought territory on January 11, 2021. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 27 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Momentum Indicator moved below the 0 level on January 14, 2021. You may want to consider selling the stock, shorting the stock, or exploring put options on TGTX as a result. In 71 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for TGTX turned negative on December 31, 2020. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 37 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
